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clinical case report
Co-occurring PTPN11 and SOS1 
gene mutations in Noonan 
syndrome: does this predict a 
more severe phenotype?
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SUMMARY
Noonan syndrome (NS) is an autosomal dominant disorder, with variable phenotypic expres-
sion, characterized by short stature, facial dysmorphisms and heart disease. Different genes of 
the RAS/MAPK signaling pathway are responsible for the syndrome, the most common are: 
PTPN11, SOS1, RAF1, and KRAS. The objective of this study was to report a patient with Noo-
nan syndrome presenting mutations in two genes of RAS/MAPK pathway in order to establish 
whether these mutations lead to a more severe expression of the phenotype. We used direct 
sequencing of the PTPN11, SOS1, RAF1, and KRAS genes. We have identified two described mu-
tations in heterozygosity: p.N308D and p.R552G in the genes PTPN11 and SOS1, respectively. 
The patient has typical clinical features similar to the ones with NS and mutation in only one 
gene, even those with the same mutation identified in this patient. A more severe or atypical 
phenotype was not observed, suggesting that these mutations do not exhibit an additive effect. 
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SUMÁRIO
A síndrome de Noonan (SN) é uma doença gênica autossômica dominante, com expressão 
clínica variável, caracterizada por baixa estatura, dismorfismos faciais e cardiopatia. Diferen-
tes genes da via de sinalização RAS/MAPK são responsáveis pela síndrome, sendo as mais 
frequentes: PTPN11, SOS1, RAF1 e KRAS. O objetivo deste estudo foi relatar um paciente com 
SN que apresenta mutações em dois genes da via RAS/MAPK a fim de estabelecer se essas 
mutações levam a uma expressão mais grave do fenótipo. Utilizou-se sequenciamento direto 
dos genes PTPN11, SOS1, RAF1 e KRAS. Foram identificadas duas mutações em heterozigose 
previamente descritas: p.N308D e p.R552G nos genes PTPN11 e SOS1, respectivamente. A pa-
ciente apresenta quadro clínico típico semelhante ao dos pacientes com SN e mutação em um 
único gene, mesmo naqueles com a mesma mutação identificada na paciente. Não foi observa-
do um fenótipo mais grave ou atípico na paciente, sugerindo que as mutações não apresentam 
um efeito aditivo. Arq Bras Endocrinol Metab. 2010;54(8):717-22
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IntROdUctIOn
Noonan syndrome (NS; OMIM 163950) is an autosomal dominant disorder with an estimated 
incidence between 1/1,000 and 1/2,500 (1). The 
main clinical features, which are extremely variable, 
include short stature, facial dysmorphisms, webbed 
neck, cardiac abnormalities (especially pulmonary ste-
nosis and hypertrophic cardiomyopathy) and cryptor-
chidism in the males [Reviewed in ref. (2)].
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The molecular background was recently unveiled. 
Different genes of the RAS/MAPK signaling pathway 
are responsible for NS (Table 1) (3-11). Mutation in 
the PTPN11, SOS1, RAF1 and KRAS genes, usually 
leading to a gain-of-function, is found in approximately 
70% of NS (12) cases. Mutations in other genes in this 
pathway are rarely described in NS patients, including 
BRAF, MEK1, MEK2, SHOC2 and CBL (12,13).
Due to the complexity of the molecular analysis in 
NS, previous studies have screened patients initially for 
the PTPN11 gene, the main gene in the syndrome. 
Only in those patients who were negative for mutations 
in this gene, were the other genes subsequently ana-
lyzed until a mutation was found. 
Several hormones, including growth hormone 
(GH) (2) and insulin-like growth factor 1 (IGF-1), 
act through receptors that stimulate the RAS/MAPK 
pathway, and therefore, NS and related disorders rep-
resent a remarkable opportunity to study the implica-
tion of the RAS/MAPK pathway in different endocrine 
systems. Additionally, children with NS are frequently 
referred to endocrinologists because of short stature, 
delayed puberty and/or undescended testes in males. 
Therefore, NS is important in the differential diagnosis 
of short stature and has important implications in GH 
therapy.
Recently, two groups described NS patients pre-
senting two mutations in different RAS/MAPK path-
way-related genes (14,15). In both studies, one of 
the mutations predicted to affect the protein function 
(pathogenic mutation), while the other mutation pre-
dicted to be benign (uncertain pathogenicity). 
To evaluate if the variable expressivity in this syn-
drome is due partially to the presence of more than 
one mutation in genes of the RAS/MAPK pathway, we 
screened a cohort of NS syndrome patients for the main 
responsible genes – PTPN11, SOS1, RAF1 and KRAS. 
Herein, we report on a single patient presenting two 
pathogenic mutations in the main genes responsible for 
NS – PTPN11 and SOS1. 
cASe RepORt
The proband, a 10 year-old female, is the only child of 
non-consanguineous parents. Her mother was 22 years 
old and her father 36 years old at the time of concep-
tion, both parents had normal height (mother’s height 
= 158 cm and father´s height = 183 cm). She was born 
at term, by vaginal delivery, with a birth weight of 
2,710 g (-1.3 SDS) and length of 48 cm (-0.5 SDS). 
A heart murmur was audible and a diagnosis of pul-
monary stenosis was disclosed. She was first evaluated 
at our cardiology clinic and a cardiac surgery was in-
dicated at the age of 3 years and 3 months due to the 
presence of valvar and supravalvar pulmonary stenosis 
and ostium secundum atrial septal defect (ASD) on the 
echocardiogram. EKG showed signs of right ventricu-
lar hypertrophy. At the first evaluation she was 89 cm 
tall (height SDS = -1.8), weighed 11,100 g (body mass 
index SDS = -1.5) and her head circumference was 
47.2 cm (-1.5 SDS). She had Noonan syndrome-relat-
ed dysmorphisms (Figure 1): mild hypertelorism, left 
ptosis, slight proptosis, malocclusion, high arched pal-
ate, overfolded pinnae; webbed neck; sternal deformity 
(pectus carinatum superiorly and excavatum inferiorly); 
hepatoesplenomegaly and distal joints hiperextensibil-
ity. No evident ectodermal findings were disclosed. She 
had normal developmental milestones. Complementa-
ry exams showed normal abdominal ultrasound, spine 
X-ray, bone age, hematological studies, including factor 
XI analysis and karyotype. Ophthalmologic evaluation 
demonstrated prominent corneal nerves on slit-lamp 
exam. At the age of 10 years, she is enrolled at a regular 
school, without major difficulties. A positive family his-
tory of NS was not uncovered, either by the physical 
exam of the mother or by medical history and photo-
graphs of the father.
Figure 1. Noonan syndrome patient showing typical NS facial 
dysmorphisms: hypertelorism, left ptosis and slight proptosis.
table 1. Major genes of RAS/MAPK signaling pathway involved with 
Noonan syndrome
Locus Mutation Gene (%) Reference
12q24.1 PTPN11 29-70 (4,12)
2p22.1 SOS1 17a-28a (9,11)
3p25.1 RAF1 9b-17b (6,7)
12p12.1 KRAS 2a -6b (3,5)
a) In patients without PTPN11 gene mutation; b) In patients without PTPN11 and SOS1 genes 
mutation.
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SUbjectS And MethOdS
Molecular studies
This patient was included in an on-going cohort study 
of NS, approved by the Institutional Ethics Commit-
tee of Hospital das Clínicas da Faculdade de Medicina 
de São Paulo (HC-FMUSP). Briefly, venous blood was 
drawn for genomic DNA extraction from peripheral 
leukocytes using a salting-out protocol. 
PTPN11 exons 2-15 (Reference sequence: 
NC_000012.11), SOS1 exons 1-23 (NC_000002.11), 
RAF1 exons 7, 14, and 17 (NC_000003.11) and 
KRAS exons 2-6 (NC_000012.11) were amplified us-
ing specific intronic primers (primer sequences and am-
plification protocols will be sent upon request). PCR 
products from these exons were directly sequenced 
with dideoxy chain-termination method using a kit 
ABI PrismTM BigDye Terminator (Perkin Elmer, Fos-
ter City, CA, USA) and analyzed by an autosequencer 
ABI Prism Genetic Analyser 3100 automatic DNA 
sequencer (Perkin Elmer). Genotype sequences were 
manually observed using DNASTAR SeqMan – Laser 
Gene. New allelic variants identified in SOS1 were also 
investigated in 192 control individuals (384 alleles). 
In silico prediction of mutation effects
Missense variants identified by sequencing were classi-
fied based on their potential impact on protein func-
tion or structure, using a new version of the PolyPhen 
method (16). These predictions are based on the analy-
sis of multiple sequence alignments of homologous 
proteins, functional annotation and structural informa-
tion. PolyPhen defines the predictions of the mutations 
as follows: 1) probably damaging: it is with high con-
fidence that it is supposed to affect protein function or 
structure, 2) possibly damaging: it is supposed to affect 
protein function or structure and 3) benign: it is most 
likely that it lacks any phenotypic effect.
Another investigation of the variations identified in 
this study include a tool for whole genome compara-
tive analysis of the human genome using the VISTA 
Genome Browser (17). Multiple amino acid align-
ments were built using wild-type and mutated human 
sequence and wild-type Fugu rubripes, Pan troglodytes, 
Gallus gallus, Xenopus tropicalis, Canis familiaris, Da-
nio rerio and Trichoplax adhaerens sequences.
Laboratory evaluation
GH and insulin were measured by an immunofluoro-
metric assay (AutoDELFIA®, PerkinElmer, Waltham, 
MA, USA). Cut-off levels used to rule out GH defi-
ciency diagnosis after stimulation test were peak GH 
levels > 3.3 µg/L: (18). IGF-1 and IGFBP-3 were 
measured by chemiluminescence assays (IMMULITE, 
Diagnostic Products Corporation – DPC, Los Angeles, 
CA, USA) and expressed as SDS for age and sex ac-
cording to reference values provided by the assay kit. 
ReSULtS
Molecular results
Positive molecular findings are summarized in table 2. 
No mutation was identified in the KRAS and RAF1 
genes. One previously described mutation in PTPN11 
was identified in the heterozygous state [p.N308S 
(14)]. Direct sequencing of SOS1 revealed two hetero-
zygous allelic variants: one previously described muta-
tion [p.R552G (9)] and a new variant p.A708T. For the 
two previously described mutations, the alterations are 
predicted to be probably damaging and amino acid res-
idues are conserved between different species. On the 
other hand, the new alteration found (p.A708T in the 
SOS1 gene), is predicted to be benign and is not con-
served among species. Furthermore, a control group 
was screened and this specific gene alteration was pres-
ent in 4 out of 192 control individuals in the hetero-
zygous state (allelic frequency of 1%), characterizing a 
polymorphism in our population. The patient’s mother 
had none of these three described allelic variants. Un-
fortunately, DNA from the father was not available.
table 2. Summary of the mutations found in the presently described Noonan syndrome patient
Gene exon nucleotide Amino Acid described PolyPhen VISTA  Genome Browser
PTPN11 8 c.A1121G p.N308S Yesa Probably damaging Conserved
SOS1 10 c.A1654G p.R552G Yesb Probably damaging Conserved
SOS1 13 c.G2122A p.A708T No Benign No conserved
a) Literature for p.N308S in PTPN11 gene (10,19-23); b) Literature for p.R552G in SOS1 gene (9,11,24-26); PolyPhen (16); VISTA Genome Browser (17).
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phenotype analysis
The present patient, who has co-occurring mutations 
in the PTPN11 and SOS1 genes, did not have a more 
severe phenotype than those NS patients with muta-
tions only in PTPN11 or SOS1. In our group we iden-
tified five other NS patients with p.N308S mutation 
in the PTPN11 gene and one patient with p.R552G 
mutation in the SOS1 gene (14,27). The phenotype of 
these patients did not significantly differ from the pa-
tient harboring both mutations (Table 3).
table 3. Clinical phenotype of NS patient with co-occurrence of PTPN11 
(p.N308D) and SOS1 (p.R552G) pathogenic mutations in comparison with 
NS patients with only one of the genes.
Mutation(s)
p.n308S 
(PTPN11) and 
p.R552G 
(SOS1)
p.n308S 
(PTPN11)
p.R552G 
(SOS1)
Patient(s) 1 5 1
Typical facial features + 5/5 +
Pulmonary stenosis + 2/5 -
Sternal deformity + 3/5 +
Development delay - 2/5 -
Height SDSa -1.8 -1.2 to -3.9 -1.5
Height SDSb 0.2 -2.1 to +1.2 0.4
BMI SDS -1.5 -1.0 to 0.1 1.3
Height SDS was calculated using age- and gender-specific norms (a) for general population (28) 
and (b) specific for Noonan syndrome patients (29). 
hormonal analysis
Patient had normal metabolic evaluation for her age: 
fasting glucose and insulin were 77 mg/dL (4.2 
mmol/L) and < 2.5 µU/mL, respectively. She also had 
an unremarkable lipid profile (Total cholesterol of 136 
mg/dL, HDS-cholesterol of 40 mg/dL and triglycer-
ides of 98 mg/dL). IGF-1 and IGFBP-3 levels were 
at the lower normal range for sex and age (61 µg/L 
and 2.0 µg/mL, respectively; both corresponding to 
-1.7 SDS). During the clonidine test to evaluate GH 
secretion, the patient had a GH peak of 8.5 µg/L, rul-
ing out GH deficiency. These hormonal findings were 
similar to the ones observed in other NS patients in our 
group (30). 
dIScUSSIOn
In the present study we described a NS patient with 
simultaneous pathogenic mutations in two of the most 
common genes associated with NS – PTPN11 and 
SOS1. The patient has typical features of NS − short 
stature, classic facial features, webbed neck and the spe-
cific heart defect (pulmonary stenosis associated with 
atrial septal defect). 
Missense heterozygous mutations in the PTPN11 
gene are found in approximately 50% of NS patients 
(19), clustered especially in exons 3, 8, and 13. Dif-
ferent from exons 3 and 13, in which the mutations 
are spread, mutations in exon 8 mainly involve residue 
308. Indeed, the most frequent mutation found in NS 
is p.N308D (10,19). Mutation p.N308S has also been 
found in several studied patients (10,19-23). 
Regarding the SOS1 gene, two gene alterations were 
found in our patient. The p.R552G is a known patho-
genic mutation, the most frequent one in this gene as-
sociated with NS (9,11,24-26). Concerning the novel 
p.A708T, additional analysis (in silico analysis and a 
control group test) showed that this gene alteration is a 
polymorphism in our population and most probably is 
not associated to significant phenotypic effects.
Although a clear genotype-phenotype correlation in 
NS has not been established, patients presenting mu-
tations in PTPN11 tend to show a higher prevalence 
of pulmonary stenosis, short stature, sternal deformity 
and bleeding diathesis (10,19). Specifically for the mu-
tation p.N308D, Tartaglia and cols. (19) demonstrated 
that the patients required less special education, com-
pared to other described mutations in PTPN11 gene. 
For the SOS1 gene, patients presenting mutations in 
this gene showed more ptosis, ectodermal signs, such as 
keratosis pilaris and curly hair, and normal intelligence 
(11). Roberts and cols. (25) showed that their patients 
also had a high frequency of pulmonary stenosis, but 
ASD was relatively rare. On the other hand, Tartaglia 
and cols. (9) found less short stature in their patients. 
The proband here presented does not show atypical 
findings or a more severe phenotype than NS patients 
with isolate mutations – even when compared to pa-
tients with p.N308S or pR552G mutations in PTPN11 
and SOS1, respectively. Some of the features presented 
by our patient are common to mutations in both genes, 
such as the typical facial features and the cardiac lesion 
– valvar pulmonary stenosis. On the other hand, the 
proband showed short stature, ASD and lack of evident 
ectodermal findings, which is more consistent with 
the phenotype of patients harboring mutations in the 
PTPN11 gene (9-11,19,25).
The genes here involved (PTPN11 and SOS1), cod-
ing for upstream proteins of the RAS/MAPK signal-
ing pathway, are closely connected to SHC and GRB2 
Co-occurring mutations in Noonan syndrome
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proteins. All these proteins belong to the same complex 
that has the function of exchanging GDP for GTP to 
activate the RAS-RAF-MEK-ERK cascade. Mutations 
in PTPN11 and SOS1 reported here, commonly lead 
to a gain-of-function of the RAS/MAPK pathway. The 
fact that we did not observe a more severe phenotype 
in our patient with mutations in both genes suggests 
that mutations in these two genes do not have additive 
effects, leading to a typical NS phenotype.
The occurrence of two known pathogenic mu-
tations in genes of the RAS/MAPK pathway in NS 
has not been described before. Two previous stud-
ies (14,15), including one from our group, showed 
the presence of one known pathogenic mutation and 
another gene alteration that probably functions as a 
modifier. We described a NS patient presenting the 
pathogenic p.N308D mutation in the PTPN11 gene 
and also the p.N85S mutation in the KRAS gene (14). 
The patient presented typical features of NS and learn-
ing disabilities, which is not common, but far from an 
exception, in individuals with the p.N308D mutation 
in the PTPN11 gene. Ekvall and cols. (15) reported 
on a NS patient presenting mild psychomotor develop-
mental delay, hoarse voice, osteoporosis, loose anagen 
hair, gingival hyperplasia, spinal neuroblastoma and 
liver haemangioma, and mutations in the SHOC2 gene 
(p.S2G) and PTPN11 gene (p.G409A). The mother, 
presenting only short stature, also showed this lat-
ter gene alteration. The authors concluded that the 
p.G409A mutation in the PTPN11 gene represents a 
mild partial mutation, acting as a modifier. On the oth-
er hand, the report of two pathogenic mutations in pa-
tients presenting neurofibromatosis-Noonan syndrome 
(NFNS) have been previously described (31,32) but in 
both cases one of the parents had one of the mutations, 
which increases the chance of this occurrence. 
The rate of new mutations is very low in general and 
the presence of two mutations in our case is out of the 
ordinary. Unfortunately, we were not able to rule out 
with certainty that the father comprised one of these 
mutations, but photographs failed to show any facial fea-
tures suggestive of NS. Besides, there is no history of 
heart problems and he has a height of 1 SD above the 
mean. 
The great variability in the phenotype of NS patient 
still remains to be properly elucidated. The presence 
of two different pathogenic mutations in our patient, 
which is an extremely rare event, failed to show an im-
portant effect in the phenotype. We can speculate that 
subtler gene alterations, such as polymorphisms of sin-
gle nucleotides (SNPs) in genes of this pathway or even 
other genes associated with environmental factors may 
modulate the phenotype.
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